APTORUM GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.28 USD | -3.65% |
|
-8.17% | +115.63% |
| Sales 2021 | 1.54 123.42 | Sales 2022 | 1.3 103.74 | Capitalization | 19.64M 1.57B |
|---|---|---|---|---|---|
| Net income 2021 | -25M -2B | Net income 2022 | -9M -720M | EV / Sales 2021 | 29,374,835 x |
| Net cash position 2021 | 8.15M 652M | Net Debt 2022 | 4.87M 390M | EV / Sales 2022 | 18,915,284 x |
| P/E ratio 2021 |
-2.1
x | P/E ratio 2022 |
-2
x | Employees | 19 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 38.85% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -3.65% | ||
| 1 week | -8.17% | ||
| Current month | -44.36% | ||
| 1 month | -39.31% | ||
| 3 months | +193.33% | ||
| 6 months | +194.97% | ||
| Current year | +115.63% |
1 week
5.15
6.22
1 month
5.0411.19
Current year
1.3517.49
1 year
1.3517.49
3 years
1.3535.40
5 years
1.35332.80
10 years
1.35332.80
| Managers | Title | Age | Since |
|---|---|---|---|
Ian Huen
FOU | Founder | 44 | 12/09/10 |
Martin Siu
DFI | Director of Finance/CFO | - | 30/06/22 |
Wai-Yip Lee
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/03/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mirko Scherer
BRD | Director/Board Member | 55 | 30/09/17 |
Ian Huen
FOU | Founder | 44 | 12/09/10 |
Clark Cheng
CTO | Chief Tech/Sci/R&D Officer | 44 | 01/01/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 5.28 | -3.65% | 27,222 |
| 25/04/24 | 5.48 | -1.44% | 39,317 |
| 24/04/24 | 5.56 | +1.09% | 19,311 |
| 23/04/24 | 5.5 | -2.83% | 34,587 |
| 22/04/24 | 5.66 | -1.57% | 19,463 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Aptorum Group Limited is United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's business segments include Therapeutics and Non-Therapeutics. Therapeutics segment is engaged in developing various drug molecules and certain technologies for treatment of human disease conditions. Two of the Companyâs lead projects, ALS-4 and SACT-1, target infectious disease and cancer, including orphan oncology indications. Non-Therapeutics segment encompasses three businesses: diagnostics projects including PathsDx Test, natural supplements including NativusWell, and AML Clinic. PathsDx Test is a novel molecular-based rapid pathogen identification and detection diagnostics technology, which is under co-development with A*STAR.
Sector
Pharmaceuticals
Calendar
09/09/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +115.63% | 28.89M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- APM Stock
